Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference ...

Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...

Adjusted EPS of $1.69 exceeded the estimate of $1.58. Q4 revenue was $627.7 million, slightly below the $629 million estimate. Ingrezza remains the main revenue driver, with a 23% increase in ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive ...